AHA blog: PhRMA report misleads on drug costs
Instead of attacking hospitals and health systems caring for patients during the COVID-19 pandemic, PhRMA should instead focus on lowering the costs of drugs for Americans, writes AHA Executive Vice President Tom Nickels.
Related News Articles
Headline
The 1st U.S. Circuit Court of Appeals Jan. 7 denied the government’s motion for a stay in a lawsuit filed by the AHA, the Maine Hospital Association and four…
Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program. “When…